Mark O'Neill

Dignity Sciences Ltd. operates as a biopharmaceutical company that focuses on discovering and developing new therapeutics based upon novel semi-synthetic fatty acid and derivatives. It specializes in skin treatments, cardiovascular, and pulmonary diseases. The company was founded in 2010 and is headquartered in Dublin, Ireland.

Dignity Sciences Ltd. operates as a biopharmaceutical company that focuses on discovering and developing new therapeutics based upon novel semi-synthetic fatty acid and derivatives. It specializes in skin treatments, cardiovascular, and pulmonary diseases. The company was founded in 2010 and is headquartered in Dublin, Ireland.

Dignity Sciences Ltd. operates as a biopharmaceutical company that focuses on discovering and developing new therapeutics based upon novel semi-synthetic fatty acid and derivatives. It specializes in skin treatments, cardiovascular, and pulmonary diseases. The company was founded in 2010 and is headquartered in Dublin, Ireland.

Dignity Sciences Ltd. operates as a biopharmaceutical company that focuses on discovering and developing new therapeutics based upon novel semi-synthetic fatty acid and derivatives. It specializes in skin treatments, cardiovascular, and pulmonary diseases. The company was founded in 2010 and is headquartered in Dublin, Ireland.

Dignity Sciences Ltd. operates as a biopharmaceutical company that focuses on discovering and developing new therapeutics based upon novel semi-synthetic fatty acid and derivatives. It specializes in skin treatments, cardiovascular, and pulmonary diseases. The company was founded in 2010 and is headquartered in Dublin, Ireland.